John R Ticehurst1,2,3, Nora Pisanic4, Michael S Forman3, Carly Ordak4, Christopher D Heaney1,4,5, Edgar Ong6, Jeffrey M Linnen6, Paul M Ness7,8, Nan Guo1, Hua Shan9, Kenrad E Nelson1,2. 1. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 2. Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 3. Division of Medical Microbiology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 4. Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 5. Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 6. Hologic Inc, San Diego, California. 7. Division of Transfusion Medicine, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 8. Division of Oncology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 9. Department of Transfusion Medicine, Stanford University, Palo Alto, California.
Abstract
BACKGROUND: Hepatitis E virus (HEV) can inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated. STUDY DESIGN AND METHODS: To identify donations that contained HEV RNA and were linked to patient-recipients with antibody evidence of HEV exposure, we assayed samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient repository that represents 13,201 linked donations and 3384 transfused patients. Posttransfusion samples, determined to contain IgG anti-HEV by enzyme-linked immunosorbent assay, were reassayed along with corresponding pretransfusion samples for seroconversion (incident exposure) or at least fourfold IgG anti-HEV increase (reexposure). HEV-exposed patients were linked to donations in which HEV RNA was then detected by reverse-transcription quantitative polymerase chain reaction, confirmed by transcription-mediated amplification, and phylogenetically analyzed as subgenomic cDNA sequences. RESULTS: Among all patients, 19 of 1036 (1.8%) who had IgG anti-HEV before transfusion were reexposed; 40 of 2348 (1.7%) without pretransfusion IgG anti-HEV seroconverted. These 59 patients were linked to 257 donations, 1 of which was positive by reverse-transcription quantitative polymerase chain reaction and transcription-mediated amplification. Plasma from this donation contained 5.5 log IU/mL of HEV RNA that grouped with HEV genotype 3, clade 3abchij. The patient-recipient of RBCs from this donation had a greater than eightfold IgG increase; however, clinical data are unavailable. CONCLUSIONS: This is the first report of probable HEV transmission via transfusion in the United States, although it has been frequently observed in Europe and Japan. Additional data on the magnitude of the risk in the United States are needed.
BACKGROUND:Hepatitis E virus (HEV) can inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated. STUDY DESIGN AND METHODS: To identify donations that contained HEV RNA and were linked to patient-recipients with antibody evidence of HEV exposure, we assayed samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient repository that represents 13,201 linked donations and 3384 transfused patients. Posttransfusion samples, determined to contain IgG anti-HEV by enzyme-linked immunosorbent assay, were reassayed along with corresponding pretransfusion samples for seroconversion (incident exposure) or at least fourfold IgG anti-HEV increase (reexposure). HEV-exposed patients were linked to donations in which HEV RNA was then detected by reverse-transcription quantitative polymerase chain reaction, confirmed by transcription-mediated amplification, and phylogenetically analyzed as subgenomic cDNA sequences. RESULTS: Among all patients, 19 of 1036 (1.8%) who had IgG anti-HEV before transfusion were reexposed; 40 of 2348 (1.7%) without pretransfusion IgG anti-HEV seroconverted. These 59 patients were linked to 257 donations, 1 of which was positive by reverse-transcription quantitative polymerase chain reaction and transcription-mediated amplification. Plasma from this donation contained 5.5 log IU/mL of HEV RNA that grouped with HEV genotype 3, clade 3abchij. The patient-recipient of RBCs from this donation had a greater than eightfold IgG increase; however, clinical data are unavailable. CONCLUSIONS: This is the first report of probable HEV transmission via transfusion in the United States, although it has been frequently observed in Europe and Japan. Additional data on the magnitude of the risk in the United States are needed.
Authors: Maja Kodani; Nourine A Kamili; Alexandra Tejada-Strop; Amanda Poe; Maxine M Denniston; Jan Drobeniuc; Saleem Kamili Journal: J Med Virol Date: 2016-12-26 Impact factor: 2.327
Authors: Sally A Baylis; Victor M Corman; Edgar Ong; Jeffrey M Linnen; C Micha Nübling; Johannes Blümel Journal: Transfusion Date: 2016-07-24 Impact factor: 3.157
Authors: D Huzly; M Umhau; D Bettinger; T Cathomen; F Emmerich; P Hasselblatt; H Hengel; R Herzog; O Kappert; S Maassen; E Schorb; C Schulz-Huotari; R Thimme; R Unmüssig; J J Wenzel; M Panning Journal: Euro Surveill Date: 2014-05-29
Authors: X J Meng; B Wiseman; F Elvinger; D K Guenette; T E Toth; R E Engle; S U Emerson; R H Purcell Journal: J Clin Microbiol Date: 2002-01 Impact factor: 5.948
Authors: S H Kleinman; S A Glynn; M J Higgins; D J Triulzi; J W Smith; C C Nass; George Garratty; E L Murphy; G F LeParc; G B Schreiber; M R King; M E Chamberland; G J Nemo Journal: Transfusion Date: 2005-07 Impact factor: 3.157
Authors: A Dereeper; V Guignon; G Blanc; S Audic; S Buffet; F Chevenet; J-F Dufayard; S Guindon; V Lefort; M Lescot; J-M Claverie; O Gascuel Journal: Nucleic Acids Res Date: 2008-04-19 Impact factor: 16.971
Authors: Paul K Sue; Nora Pisanic; Christopher D Heaney; Michael Forman; Alexandra Valsamakis; Annette M Jackson; John R Ticehurst; Robert A Montgomery; Kathleen B Schwarz; Kenrad E Nelson; Wikrom Karnsakul Journal: Open Forum Infect Dis Date: 2016-01-18 Impact factor: 3.835
Authors: Anna-Maria Kapsch; Maria R Farcet; Andreas Wieser; Monazza Q Ahmad; Tomoyuki Miyabayashi; Sally A Baylis; Johannes Blümel; Thomas R Kreil Journal: Transfusion Date: 2020-08-13 Impact factor: 3.157
Authors: Kenneth E Sherman; Shyam Kottilil; Susan D Rouster; Enass A Abdel-Hameed; Ceejay L Boyce; Heidi L Meeds; Norah Terrault; M Tarek Shata Journal: AIDS Res Hum Retroviruses Date: 2021-05-10 Impact factor: 1.723
Authors: Harini Sooryanarain; Connie L Heffron; Dolores E Hill; Jorrell Fredericks; Benjamin M Rosenthal; Stephen R Werre; Tanja Opriessnig; Xiang-Jin Meng Journal: Emerg Infect Dis Date: 2020-02 Impact factor: 6.883